טוען...
CAR T Cells: A Snapshot on the Growing Options to Design a CAR
Adoptive cell therapy of malignant diseases with chimeric antigen receptor (CAR) modified T cells rapidly advanced from pre-clinical models to commercial approvals within 2 decades. CARs redirect patient's T cells towards cancer cells and activate the engineered cells for a cytolytic attack res...
שמור ב:
| הוצא לאור ב: | Hemasphere |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wolters Kluwer Health
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6745938/ https://ncbi.nlm.nih.gov/pubmed/31723811 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000172 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|